BOSTON, April 28, 2021 /PRNewswire/ -- Stealth
BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology
company focused on the discovery, development, and
commercialization of novel therapies for diseases involving
mitochondrial dysfunction, today announced that the company will
have a poster presentation with a live discussion at the upcoming
2021 Association for Research in Vision and Ophthalmology (ARVO)
Virtual Annual Meeting which is being held May 1-7, 2021. The poster showcases data that are
consistent with elamipretide's mechanism of action and provides
further support for the company's design of ReCLAIM-2, Stealth's
Phase 2 trial focused on earlier stages of geographic atrophy which
recently completed enrollment. The presentations will be available
to conference attendees via the conference website.
The presentation details are as follows:
- Title: Association of Ellipsoid Zone Integrity and Treatment
Response in Non-Neovascular AMD Treated with Subcutaneous
Elamipretide
- Date and Time: May 1,
3:15 p.m. - 4:45 p.m. ET with live
discussion from 4:45 p.m. –
5:00 p.m. ET.
About ReCLAIM-2
ReCLAIM-2 is a phase 2 randomized, double-masked,
placebo-controlled study to evaluate the efficacy and
pharmacokinetics of elamipretide in patients with dry age-related
macular degeneration (AMD) with geographic atrophy (GA). The
ReCLAIM-2 study completed enrollment with 176 patients. The primary
endpoint of the 48-week study will measure the low-luminance
best-corrected visual acuity, which assesses visual function under
low light conditions meant to represent dusk or indoor (artificial)
lighting. Secondary functional endpoints are change in
low-luminance reading acuity and best-corrected visual acuity
(BCVA). Secondary imaging endpoints assessing the rate of
progression of the disease include GA area as measured by fundus
autofluorescence and optical coherence tomography.
About Stealth
We are a clinical-stage biotechnology company focused on the
discovery, development, and commercialization of novel therapies
for diseases involving mitochondrial dysfunction. Mitochondria,
found in nearly every cell in the body, are the body's main source
of energy production and are critical for normal organ function.
Dysfunctional mitochondria characterize a number of rare genetic
diseases and are involved in many common age-related diseases,
typically involving organ systems with high energy demands such as
the heart, the eye, and the brain. We believe our lead product
candidate, elamipretide, has the potential to treat both rare
metabolic cardiomyopathies, such as Barth, Duchenne muscular
dystrophy and Friedreich's ataxia, rare mitochondrial diseases
entailing nuclear DNA mutations, as well as ophthalmic diseases
entailing mitochondrial dysfunction, such as dry age-related
macular degeneration and Leber's hereditary optic neuropathy. We
are evaluating our second-generation clinical-stage candidate,
SBT-272, and our new series of small molecules, SBT-550, for rare
neurological disease indications following promising preclinical
data. We have optimized our discovery platform to identify novel
mitochondria-targeted compounds which may be nominated as
therapeutic product candidates or utilized as mitochondria-targeted
vectors to deliver other compounds to mitochondria.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-poster-presentation-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-virtual-annual-meeting-301279532.html
SOURCE Stealth BioTherapeutics Inc.